Physician profile
Nathan M Bloom
NPI 1164629218
$5,154.27
in general payments reported to CMS, 2019-2025
48 companies · $508 in 2025
The $508 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,744 · 2020: $374 · 2021: $479 · 2022: $623 · 2023: $1,411 · 2024: $14.99 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862 · Education: $72.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,862.13 |
| Education | $72.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $888.40 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Lilly USA, LLC | $570.79 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $380.32 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $307.81 | 2019-2025 | |
| Novo Nordisk INC | $300.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.41 | 2019-2025 | Jardiance, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $244.62 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $224.28 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Allergan, INC. | $214.63 | 2019-2020 | |
| Glaxosmithkline, LLC. | $179.38 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.44 | 2019-2023 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $162.96 | 2019-2023 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $83.15 | 2021 | |
| Jazz Pharmaceuticals INC. | $68.77 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $63.25 | 2019-2020 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.